Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II trial of izokibep in ankylosing spondylitis commences dosing

Aug. 26, 2021

CPI-613 advances into phase II evaluation in biliary tract cancer

Aug. 26, 2021

New phase I/II trial investigates RVU-120 in relapsed/refractory metastatic or advanced solid tumors

Aug. 26, 2021

HUTCHMED begins phase Ib/II study of fruquintinib with tislelizumab in TNBC and endometrial cancer

Aug. 26, 2021

Janssen targets DHODH with new compounds for acute myelogenous leukemia

Aug. 26, 2021

Data presented for Almirall's JAK inhibitor LAS-200019

Aug. 26, 2021

Blade receives IND clearance for phase I study of cudetaxestat for IPF

Aug. 26, 2021

Mutational profiling gives clues to development, new puzzles about disease

Aug. 26, 2021

Memorial Sloan-Kettering Cancer Center describes prodrugs useful in adoptive cell therapy

Aug. 26, 2021

New CREB-2 inhibitors discovered at Evotec International

Aug. 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...